# Regulators Knew This Marijuana Product Was Harming People. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/regulators-knew-this-marijuana-product-was-harming-people-it-stayed-on-shelves/ > **Published:** 2026-09-04T07:06:05-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:45:54-04:00 > **Clinical Summary:** Cannabis product safety testing standards vary by state. Learn what third-party COAs reveal and how clinicians can guide safer patient selection. --- ✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicySafetyTHCIndustryDosingMental HealthResearch Clinical Summary # Clinical Summary Regulatory oversight of cannabis products remains fragmented, with evidence of harm reaching authorities without corresponding market removal or public warning. This case demonstrates a critical gap in post-market surveillance and enforcement mechanisms for cannabis edibles and extracts, particularly regarding products marketed as safer alternatives that may pose unanticipated health risks. The failure to act on documented harms raises questions about the adequacy of current state-level regulatory frameworks and the extent to which clinicians and patients can rely on dispensary guidance for product safety. For practitioners recommending cannabis or counseling patients on product selection, this highlights the absence of centralized adverse event reporting systems comparable to FDA oversight of pharmaceuticals. Clinicians should remain vigilant about eliciting detailed product information from cannabis-using patients and maintain awareness that “regulated” does not guarantee safety or efficacy equivalent to traditional pharmaceutical standards. Clinical Perspective 💊 The regulatory gap between cannabis product approval and post-market safety monitoring presents a meaningful clinical challenge, particularly when vulnerable populations like diabetics are targeted with alternative formulations that may carry understudied risks. While Colorado’s early legalization provided a natural experiment in cannabis regulation, the apparent delay in removing potentially harmful products despite regulator awareness highlights how traditional pharmacovigilance systems may not adequately capture cannabis-related adverse events in community settings. Clinicians should recognize that “sugar-free” or “health-conscious” marketing claims for cannabis products often outpace rigorous safety data, and patients seeking these alternatives may not spontaneously report harms to providers or regulatory bodies. Given the incomplete transparency in supply chains and variable testing standards across jurisdictions, practitioners should actively inquire about specific cannabis product types and formulations when taking substance use histories, particularly for patients with metabolic conditions or those self-managing symptoms. A practical approach is to counsel patients that cannabis 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Regulators%20Knew%20This%20Marijuana%20Product%20Was%20Harming%20People.%20It%20Stayed%20on%20Shelves%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D75817)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D75817)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Regulators%20Knew%20This%20Marijuana%20Product%20Was%20Harming%20People.%20It%20Stayed%20on%20Shelves%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D75817)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [How 2026 Cannabis Local Bans Impact the Illicit Market](https://cedclinic.com/california-cannabis-local-bans-illicit-market/) 📰 Source: [https://www.propublica.org/article/colorado-marijuana-enforcement-division-sima-sciences-midnight-drops](https://www.propublica.org/article/colorado-marijuana-enforcement-division-sima-sciences-midnight-drops) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) #### 📄 Printable 1-Page Physician Patient Guide Download or print Dr. Benjamin Caplan’s official clinical reference guide to share with your healthcare team. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).